突发情况会导致医生出诊时间、出诊地点、挂号费用等改变,具体请以医院官方信息为准。
1.中华医学科技三等奖:提高肝癌治疗效果的系列研究(证书号:200903189P0807)
2.广东省科技进步而等奖:小肝癌经皮射频微创治疗的临床研究(证书号:B14-0-20-05-R04)
3.广东省科技进步二等奖:综合外科与介入提高肝癌疗效的临床实验研究。(证书号:2001-医-2-008-R02)
4.广州市科技进步三等奖:多学科融合提高肝癌疗效的临床与实验研究(证书号:医-3-008-R02)
5.中国高校自然科学科技进步二等奖:多学科融合提高肝癌疗效的临床与实验研究(证书号:2001-236)
近年来以通信作者或第一作者发表的文章:
1.Wang, J.H., Wei, W., Xu, J., Guo, Z.X., Xiao, C.Z., Zhang, Y.F., Jian, P.E., Wu, X.L., Shi, M., Guo, R.P., Elevated expression of Cripto-1 correlates with poor prognosis in hepatocellular carcinoma. Oncotarget 2015, 6(33), 35116-28.
2.Li Shaohua Wang Qiaoxuan Sun Peng Li Qing Yang Zhongyuan Shi Ming Wei Wei Guo Rongping. Surgical Strategy for Hepatocellular Carcinoma Patients with Portal/Hepatic Vein Tumor Thrombosis. PLOS ONE June 15, 2015
3.Zhong, C., Li, M.Y., Chen, Z.Y., Cheng, H.K., Hu, M.L., Ruan, Y.L., Guo, R.P., MicroRNA-200a inhibits epithelial-mesenchymal transition in human hepatocellular carcinoma cell line. International journal of clinical and experimental pathology 2015, 8(9), 9922-31.
4.Zhang, Y.F., Wei, W., Guo, Z.X., Wang, J.H., Shi, M., Guo, R.P., Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus. Japanese journal of clinical oncology 2015, 45(9), 837-43.
5.Zhang, Y.F., Guo, R.P., Zou, R.H., Shen, J.X., Wei, W., Li, S.H., OuYang, H.Y., Zhu, H.B., Xu, L., Lao, X.M., Shi, M., Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study. European radiology 2015.
6.Xiao, C.Z., Wei, W., Guo, Z.X., Li, S.H., Zhang, Y.F., Wang, J.H., Shi, M., Guo, R.P., A prognosis model for patients with hepatocellular carcinoma and portal vein tumor thrombus following hepatic resection. Oncology letters 2015, 10(5), 2787-2794..
7.Wang, J.H., Wei, W., Guo, Z.X., Shi, M., Guo, R.P., Decreased Cezanne expression is associated with the progression and poor prognosis in hepatocellular carcinoma. Journal of translational medicine 2015, 13, 41.
8.Zhong, C., Li, H.D., Liu, D.Y., Xu, F.B., Wu, J., Lin, X.M., Guo, R.P., Clinical study of hepatectomy combined with Jianpi Huayu Therapy for hepatocellular carcinoma. Asian Pacific journal of cancer prevention : APJCP 2014, 15(14), 5951-7.
9.Li, S.H., Wei, W., Guo, R.P., Shi, M., Guo, Z.X., Chen, Z.Y., Xiao, C.Z., Cai, M.Y., Zheng, L., Long-term outcomes after curative resection for patients with macroscopically solitary hepatocellular carcinoma without macrovascular invasion and an analysis of prognostic factors. Medical oncology 2013, 30(4), 696.
10.Li, S.H., Guo, Z.X., Xiao, C.Z., Wei, W., Shi, M., Chen, Z.Y., Cai, M.Y., Zheng, L., Guo, R.P., Risk factors for early and late intrahepatic recurrence in patients with single hepatocellular carcinoma without macrovascular invasion after curative resection. Asian Pacific journal of cancer prevention : APJCP 2013, 14(8), 4759-63.
11.Zhong, C., Wei, W., Su, X.K., Li, H.D., Xu, F.B., Guo, R.P., Serum and tissue vascular endothelial growth factor predicts prognosis in hepatocellular carcinoma patients after partial liver resection. Hepato-gastroenterology 2012, 59(113), 93-7.
12.Peng, Z.W., Guo, R.P., Zhang, Y.J., Lin, X.J., Chen, M.S., Lau, W.Y., Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Cancer 2012, 118(19), 4725-36.
13.Chen, Z.Y., Shi, M., Peng, L.X., Wei, W., Li, X.J., Guo, Z.X., Li, S.H., Zhong, C., Qian, C.N., Guo, R.P., Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis. Journal of translational medicine 2012, 10, 245.
14.Luo, J., Guo, R.P., Lai, E.C., Zhang, Y.J., Lau, W.Y., Chen, M.S., Shi, M., Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Annals of surgical oncology 2011, 18(2), 413-20.
15.Zhong, C., Guo, R.P., Li, J.Q., Shi, M., Wei, W., Chen, M.S., Zhang, Y.Q., A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. Journal of cancer research and clinical oncology 2009, 135(10), 1437-45.
16.广东省抗癌协会肝癌专业委员会, 广东省医学会肝胆胰外科学分会. 肝细胞肝癌合并门静脉癌栓多学科团队综合治疗广东专家共识(2015版). 中华消化外科杂志. 2015;14: 694-701.
17.广东省抗癌协会肝癌专业委员会. 肝癌多学科综合治疗团队建立--广东专家共识(1). 临床肝胆病杂志. 2014: 1112-1115.
18.广东省抗癌协会肝癌专业委员会. 肝癌多学科联合治疗策略与方法--广东专家共识(2). 临床肝胆病杂志. 2014: 1116-1119.
19.广东省抗癌协会肝癌专业委员会. 肝癌MDT团队建立和多学科联合治疗的专家共识. 肝癌电子杂志. 2014: 4-20.
1.广东省抗癌协会肝癌专业委员会 常委副主任委员
2.广东省医疗行业协会肝胆胰外科管理分会 副主任委员
3.广东省肝脏病学会外科手术专业委员会 常务委员
4.中国抗癌协会肝癌专业委员会 委员
5.广东省医学会肝胆胰外科协会 委员
6.《岭南现代临床外科》 杂志编委
7.《中华临床医师杂志》 审稿专家
8.《中华普通外科学文献(电子版)》 审稿专家
9.《Biomedical Journals》 审稿专家
10.《Clinical Drug Investigation》 审稿专家
11.《International Journal of Cancer》 审稿专家
12.《Medical Oncology》审稿专家
肝胆肿瘤诊断及外科(包括肝移植)、介入等治疗,尤其是合并门静脉癌栓的处理
近期主持承担的科研项目:
1.2014年广东省科技计划项目:细胞因子网络预测肝癌切除术后复发风险模型的建立(项目编号:2013B021800159)
2.2012年国家自然科学基金项目面上项目:独特血管结构-ECTC在肝癌组织中的形成调控机制及其临床意义(项目批准号:81172037)
3.2012年广州市科技计划项目:药敏指导下个体化辅助性TACE治疗提高进展期肝癌手术疗效的临床研究(项目编号:2012J4100078)
4.2009年广东省科技计划项目:肝癌新生血管分化表型与靶向新生血管分子药物治疗机制的临床实验研究(项目编号:2009B080701012 )
5.2007年国家自然基金:与HBV感染有关的肝癌D4S2964位点抑癌基因的鉴定
- 2023-11-21萎缩性胃炎应该怎么治
- 2023-11-21没吃雪糕肚子为什么还疼
- 2023-11-21女人吃木瓜有什么好处
- 2023-11-20苏打水对肠胃有好处吗
- 2023-11-16自己怎样判断hpv有好转
- 2023-11-16头痛就一定是鼻咽癌吗
- 2023-11-15早期前列腺癌多久复发啊
- 2023-11-14牙周炎二度一定要拔牙吗
- 2023-11-10怎样分辨卵巢囊肿和卵泡
- 2023-11-09食道癌与鼻咽癌的区别
aru5M6CW
郭医生医术高超、医德高尚,经过他的手术治疗,使我得重新获得生命,在我住院的期间,郭医生一直给我很大的鼓励,让我很有信心战胜病魔,一个患者有个好心态对治疗有很大的帮助,非常感谢郭医生。
2011-09-03 医生:郭荣平aru5M6CW
多亏您帮母亲切除了肿瘤,目前母亲一切安好,非常感谢您对母亲的帮助,在此事先表示感谢。
2011-06-06 医生:郭荣平aruI14CW
谢谢你们,我老婆接受手术后,现在回到家里修养,各项的指标很正常,饮食也不错,这都亏你们这次手术治疗的成功,对于一个身患肝腺瘤和血管瘤的患者包括家属来说,你们就是我们的最大依靠,你们的关心让病人感到了温暖,你们的医术让患者看到了曙光,请接受我们全家人对你们的衷心感谢。
2011-02-07 医生:郭荣平